AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14747817
Drug: Intravenous prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prochlorperazine (0.15 mg/kg; maximum 10 mg)
Trial: 14747817
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (0.5 mg/kg; maximum 30 mg)
Trial: 11870177
Drug: Four cycles
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of carboplatin (AUC 6) and paclitaxel (200 mg/m² every 21 days)
Trial: 11870177
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with carboplatin/paclitaxel until progression
Trial: 11870177
Drug: Both arms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both arms received second-line weekly paclitaxel at 80 mg/m²/wk after progression
Trial: 7738617
Drug: Group 4
RxNorm normalized name: Chlamydophila psittaci biogroup 4 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4 (highest dose of IFN alpha three times per day)
Trial: 2073645
Drug: Alinidine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine (30 mg 3 times a day)
Trial: 6465630
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL of 95% ethanol in fruit juice
Trial: 26253455
Drug: Terlipressin (TP)
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (TP) 1.3 μg/kg/h + Norepinephrine (NE)
Trial: 25126874
Drug: Timed overnight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed overnight (8 hours) Urine Albumin (microalbumin) Excretion (UAE)
Trial: 24014834
Drug: MitraClip therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitraClip therapy
Trial: 15735546
Drug: HRT administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT administered in patches
Trial: 6626061
Drug: Fenoterol powder,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol powder, 200 mcg three times per day
Trial: 29910042
Drug: Belimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belimumab (10 mg/kg bodyweight, intravenous, given at day 0, 14, 28, and then every 4 weeks for a total of seven infusions)
Trial: 17169012
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (MgSO4) 4 g solution (0.1 g/ml) infused over 30 minutes
Trial: 10077917
Drug: Traditional intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional intensive therapy
Trial: 28412986
Drug: CGA (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGA (600 mg)
Trial: 28412986
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg CGA)
Trial: 16461168
Drug: Chiropractic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic treatment including high-velocity and low-amplitude manipulation, proprioceptive neuromuscular facilitation, ischemic compression of myofascial trigger points, and spinal rehabilitation exercises.
Trial: 14767084
Drug: Desferrioxamine (DFX)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (DFX) at a dose of 40 mg/kg subcutaneously, 5 days/week
Trial: 14767084
Drug: Oral deferiprone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral deferiprone (L1) at a dose of 75 mg/kg/day
Trial: 14767084
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of daily L1 at a dose of 75 mg/kg/day and DFX at a dose of 40 mg/kg/day two times per week
Trial: 11577795
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with gabexate
Trial: 11577795
Drug: Prophylactic antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antifungal therapy
Trial: 11577795
Drug: Pharmacotherapy focusing
RxNorm normalized name: ficusin
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy focusing on suppression of pro-inflammatory cytokines
Trial: 9285295
Drug: IFN-beta 1b
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-beta 1b (Betaseron) treatment
Trial: 8123056
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 35% CO2 and 65% O2 for 30 seconds
Trial: 3779921
Drug: Intracoronary streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary streptokinase (152 patients) or intracoronary streptokinase preceded by intravenous streptokinase (117 patients)
Trial: 3779921
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (264 patients)
Trial: 28124799
Drug: Social skills
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social skills training (8 weekly 2-hour sessions including cooperation, assertion, social cognitive problem solving strategies, role playing, games, and arts and crafts)
Trial: 24720731
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) administration
Trial: 19222764
Drug: Naloxone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4 mg intravenous bolus followed by continuous infusion of 20 microg kg(‐1) h(‐1))
Trial: 8016770
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline 500 micrograms four times daily
Trial: 8016770
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline 1000 micrograms four times daily
Trial: 8016770
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline 1500 micrograms four times daily
Trial: 31609072
Drug: Avocatin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avocatin B (AvoB) 50 mg per day for 60 days
Trial: 31609072
Drug: Avocatin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avocatin B (AvoB) 200 mg per day for 60 days
Trial: 25340383
Drug: Maximal medical
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal medical therapy plus LVRS
Trial: 21380990
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral micronized progesterone (MP) 400 mg
Trial: 9386146
Drug: 17beta-estradiol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol (1 mg sublingual)
Trial: 7938102
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (P) treatment (group 1)
Trial: 24146219
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liposomal doxorubicin and intravenous rituximab (500 mg/m² twice/cycle) in CODOX-M/IVAC regimen
Trial: 9113347
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of melanotan-I at a dose of 0.16 mg/kg
Trial: 9113347
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of melanotan-I at doses from 0.08 to 0.21 mg/kg
Trial: 9113347
Drug: Oral (PO)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (PO) administration of melanotan-I at a dose of 0.16 mg/kg
Trial: 25417402
Drug: Liandouqingmai recipe
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liandouqingmai recipe plus standard treatment for CHD
Trial: 16896508
Drug: Pamidronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (30 mg daily for 3 days, total 90 mg)
Trial: 14662571
Drug: 2-component acellular
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-component acellular vaccine
Trial: 14662571
Drug: 5-component pertussis
RxNorm normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-component pertussis vaccine
Trial: 14662571
Drug: whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: whole cell pertussis vaccine
Trial: 14662571
Drug: diphtheria and
RxNorm normalized name: Diphtheria and tetanus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diphtheria and tetanus toxoids vaccine alone
Trial: 14662571
Drug: 2-component pertussis
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-component pertussis vaccine with booster
Trial: 14662571
Drug: any of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: any of the vaccines
Trial: 1603140
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg of calcium citrate malate per day)
Trial: 3894128
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (pump treatment)
Trial: 23707680
Drug: Perceived treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived treatment allocation (active vs placebo)
Trial: 12885807
Drug: Monthly regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly regimen of fluorouracil and leucovorin (FULV)
Trial: 11475269
Drug: Repaglinide 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 0.25 mg
Trial: 11475269
Drug: Repaglinide 2
RxNorm normalized name: repaglinide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 2 mg
Trial: 1877851
Drug: MaxEPA (eicosapentaenoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MaxEPA (eicosapentaenoic acid) 20 g daily
Trial: 1877851
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (placebo) 20 g daily
Trial: 6781613
Drug: Oestradiol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol 150 mg
Trial: 6781613
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) 4 mg
Trial: 16422961
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection of 1 mL bimix (30 mg papaverine + 1 mg phentolamine) followed by 1 mL mixture of papaverine and chlorpromazine (30 mg papaverine + 2.5 mg chlorpromazine)
Trial: 16422961
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection of 1 mL trimix (30 mg papaverine + 1 mg phentolamine + 10 microg PGE1) followed by 1 mL mixture of papaverine, PGE1, and chlorpromazine (30 mg papaverine + 2.5 mg chlorpromazine + 10 microg PGE1)
Trial: 16422961
Drug: Various intracavernous
RxNorm normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various intracavernous injections of chlorpromazine in doses 1 mg, 2 mg, 5 mg, and 10 mg
Trial: 11883914
Drug: Chocolate condition
RxNorm normalized name: chocolate allergenic extract
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chocolate condition (CC, N=13)
Trial: 8590553
Drug: Beta-adrenergic receptor
RxNorm normalized name: Beta-adrenergic receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic receptor blockade (propranolol)
Trial: 8590553
Drug: Lactate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate infusion with propranolol
Trial: 2498781
Drug: Salbutamol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 0.5 mg i.v. in 15 min (Group A)
Trial: 2498781
Drug: Glucose 40
RxNorm normalized name: glucose 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 40 g i.v. plus 10 units insulin i.v. in 15 min (Group B)
Trial: 2498781
Drug: Salbutamol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 0.5 mg i.v., glucose 40 g i.v. and insulin 10 units i.v. over 15 min (Group C)
Trial: 31212041
Drug: Spaced instruction
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spaced instruction (four weekly sessions)
Trial: 31212041
Drug: Massed instruction
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massed instruction (two sequential days)
Trial: 25384419
Drug: Self-management Acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management Acceptance and Commitment Therapy-based training intervention (ACTr)
Trial: 21804337
Drug: Laughter therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laughter therapy (8 sessions, twice a week for 60 minutes each)
Trial: 14969665
Drug: Transdermal contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal contraceptive system (Ortho Evra)
Trial: 14969665
Drug: Transdermal contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal contraceptive system (Ortho Evra) and Oral contraceptive (OC)
Trial: 12475842
Drug: INS316 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS316 (10 to 180 mg)
Trial: 9649975
Drug: Fluoxetine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (in severe depression subsample)
Trial: 2589361
Drug: Intravenous/oral ciprofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous/oral ciprofloxacin
Trial: 25529410
Drug: Electrical Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical Stimulation (ES) following Botulinum Toxin A (BoNT/A) injection
Trial: 25529410
Drug: Control (only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (only daily stretch)
Trial: 14768494
Drug: Selective beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective beta-blockers
Trial: 1873013
Drug: Intravenous norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous norepinephrine (NE) infusion
Trial: 26660722
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity prescription
Trial: 28459237
Drug: Jinshuibao capsules
RxNorm normalized name: Jinshuibao
DrugBank: Ophiocordyceps sinensis (DB19288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinshuibao capsules (JCs)
Trial: 25106092
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight barley β‐glucan (3 g)
Trial: 25106092
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight barley β‐glucan (3 g)
Trial: 22071249
Drug: Intradermal IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal IPV (GlaxoSmithKline)
Trial: 22071249
Drug: Intramuscular IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular IPV (GlaxoSmithKline)
Trial: 22071249
Drug: Intramuscular IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular IPV (Panacea)
Trial: 22071249
Drug: Intradermal IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal IPV
Trial: 22071249
Drug: Intramuscular IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular IPV
Trial: 19671190
Drug: Artemisinin-naphthoquine combination
RxNorm normalized name: naphthoquine
DrugBank: Naphthoquine (DB16249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin-naphthoquine combination (ANQ)
Trial: 19671190
Drug: Chloroquine plus
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine plus single dose sulphadoxine-pyrimethamine (CQ+SP)
Trial: 16113582
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) and gonadotropin-releasing hormone agonist (GnRHa) treatment
Trial: 30137415
Drug: GH/GnRHa treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH/GnRHa treatment
Trial: 15620935
Drug: Intravenous isoxazolyl-penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous isoxazolyl-penicillin alone (control group)
Trial: 2191588
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (after initial monotherapy)
Trial: 6999546
Drug: PGE2-gel (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2-gel (0.05 mg, 3 ml)
Trial: 6999546
Drug: gel without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gel without PGE2
Trial: 26066587
Drug: High ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High ascorbate group (HA) with plasma ascorbate levels >1 mmol/l
Trial: 26066587
Drug: Low ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low ascorbate group (LA) with plasma ascorbate levels <1 mmol/l
Trial: 21028984
Drug: CHG-impregnated cloths
RxNorm normalized name: CHG Teat Dip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHG-impregnated cloths applied thrice weekly
Trial: 21028984
Drug: Control cloths
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cloths (Comfort Bath; Sage) applied thrice weekly
Trial: 11595689
Drug: Melanoma vaccine
RxNorm normalized name: melanoma vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melanoma vaccine with gp100(280) peptide and tetanus helper peptide
Trial: 9678294
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen 2.5 mg
Trial: 9678294
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen 5 mg
Trial: 8270757
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g added barley bran flour
Trial: 8270757
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g added barley oil extract
Trial: 8270757
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g added cellulose (control)
Trial: 2683024
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) chewable tablets at a dose of four tablets daily for 1 month
Trial: 808195
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion at 1.7 gm/kg
Trial: 808195
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion at 1.0 gm/kg
Trial: 31618704
Drug: DPFC (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPFC (cisplatin 40 mg/m2, docetaxel 40 mg/m2, 5-FU 2000 mg/m2, cetuximab 400/250 mg/m2)
Trial: 31618704
Drug: PFC (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFC (cisplatin 100 mg/m2, 5-FU 1000 mg/m2, cetuximab 400/250 mg/m2)
Trial: 25218668
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg/day by week 4, n = 38)
Trial: 24283058
Drug: T+M (2g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T+M (2g BID tinidazole for two days and vaginal suppositories of 1000 mg metronidazole at day 1 and 3)
Trial: 24283058
Drug: T+M+P (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T+M+P (same as T+M plus topical administration of vaginal probiotic from day 5)
Trial: 16957540
Drug: Vagus Nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus Nerve Stimulation (VNS) + Electroconvulsive Therapy (ECT)
Trial: 10227615
Drug: Topiramate 6
RxNorm normalized name: topiramate 69 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 6 mg/kg/day
Trial: 1684909
Drug: D-verapamil (DVPM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-verapamil (DVPM) 800 mg/day
Trial: 1684909
Drug: D-verapamil (DVPM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-verapamil (DVPM) 1200 mg/day
Trial: 1684909
Drug: D-verapamil (DVPM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-verapamil (DVPM) 600 mg/day
Trial: 1684909
Drug: D-verapamil (DVPM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-verapamil (DVPM) 150-300 mg 6 h